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Abstract 
Twist1 is a transcription factor driving epithelial-mesenchymal transition, invasion and metastasis 
of breast cancer cells. Mice with germ-line Twist1 knockout are embryonic lethal, while adult mice 
with inducible Twist1 knockout have no obvious health problems, suggesting that Twist1 is a viable 
therapeutic target for the inhibition of invasion and metastasis of breast cancer in adult patients. In 
this study, we expressed a luciferase protein or a Twist1-luciferase fusion protein in HeLa cells as 
part of a high throughput system to screen 1280 compounds in the Library of Pharmacologically 
Active Compounds (LOPAC) from Sigma-Aldrich for their effects on Twist1 protein expression. 
One of the most interesting compounds identified is tamoxifen, a selective estrogen receptor (ER) 
modulator used to treat ER-positive breast cancer. Tamoxifen treatment significantly accelerated 
Twist1 degradation in multiple cell lines including HEK293 human kidney cells, 4T1 and 168FARN 
mouse mammary tumor cells with either ectopically or endogenously expressed Twist1. Ta-
moxifen-induced Twist1 degradation could be blocked by the MG132 proteasome inhibitor, 
suggesting that tamoxifen induces Twist1 degradation through the ubiquitination-proteasome 
pathway. However, tamoxifen-induced Twist1 degradation was independent of Twist1 mRNA 
expression, estrogen signaling and MAPK-mediated Twist1 phosphorylation in these cells. Im-
portantly, tamoxifen also significantly inhibited invasive behavior in Matrigel and lung metastasis in 
SCID-bg mice of ER-negative 4T1 mammary tumor cells, which depend on endogenous Twist1 to 
invade and metastasize. These results indicate that tamoxifen can significantly accelerate Twist1 
degradation to suppress cancer cell invasion and metastasis, suggesting that tamoxifen can be used 
not only to treat ER-positive breast cancers but also to reduce Twist1-mediated invasion and 
metastasis in ER-negative breast cancers. 
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Introduction 
Owing to early diagnosis and treatment and the 
development of new therapeutic drugs and technolo-
gies, the quality of life and survival times for breast 
cancer patients are continuously improving. Howev-
er, because of its high incidence, unsatisfactory re-
sponse to therapeutic reagents, and development of 
acquired drug resistance, breast cancer remains a 









cancers express estrogen receptor (ER) α, and these 
ER-positive breast cancers are typically treated with 
selective estrogen receptor modulators (SERMs) such 
as tamoxifen or aromatase inhibitors such as anas-
trozole and letrozole in combination with other 
commonly used chemo- or radio- therapies. However, 
nearly half of these cancers exhibit unsatisfactory re-
sponses and many that do respond well initially de-
velop acquired resistance to these endocrine thera-
pies. About 15-20% of breast cancers overexpress the 
HER2 oncogene, and these HER2-positive cancers can 
be treated with the HER2-neutralizing antibodies 
such as trastuzumab in combination with other 
commonly used chemo- or radio-therapies. However, 
the response rate and the long-term clinical outcome 
of HER2 antibody-based therapy remain unsatisfac-
tory. Finally, about 15-20% of breast cancers are triple 
negative cancers, which do not express ER and pro-
gesterone receptor (PR) and do not overexpress 
HER2. These cancers still have no targeted therapy 
and can be only treated via conventional chemo- 
and/or radio-therapies. Therefore, it is important to 
identify other molecular targets and to develop new 
drugs against these targets to expand the range of 
therapeutic interventions to treat all three molecular 
subtypes of breast cancer. 
Twist1 is a basic helix-loop-helix (bHLH) do-
main-containing transcription factor that binds the 
Nde1 E-box to activate or repress gene expression [1, 
2]. Twist1 is essential for mesoderm specification and 
differentiation during embryonic development [1, 3]. 
Twist1 germ-line knockout mouse embryos die with 
unclosed cranial neural tubes and defective head 
mesenchyme, somites and limb buds [3]. Heterozy-
gous loss-of-functional mutations of the human 
Twist1 gene cause Saethre-Chotzen syndrome [4, 5]. 
Interestingly, in adult mice Twist1 protein is only de-
tected in a few cell types including the dermal papilla 
of the skin and fibroblasts in the mammary gland. 
Inducible knockout of Twist1 in mice older than 2 
weeks significantly prolongs the hair growth cycle 
without causing any obvious health problem [6]. 
These findings indicate that although Twist1 is abso-
lutely required for embryonic development, its func-
tion is not essential for maintaining a generally 
healthy condition of adult animal. 
Importantly, Twist1 is expressed in many types 
of cancer cells including breast cancer cells, and its 
expression is usually associated with invasive and 
metastatic cancer phenotypes [2, 7]. Twist1 drives 
epithelial-mesenchymal transition (EMT), migration 
and invasion of cancer cells, and hence promotes 
cancer metastasis [2, 7-9]. Twist1 stability and func-
tion are enhanced by its phosphorylation mediated by 
MAPKs, one of the major cancer-driving pathways 
downstream of tyrosine receptor kinases and ras on-
coproteins [10]. Twist1 promotes EMT in part by di-
rectly repressing E-cadherin and ER expression by 
recruiting the nucleosome remodeling and deacety-
lase (NuRD) complex for gene repression [8, 11] and 
by upregulating Bmi1, AKT2, YB-1 and WNT5A [2, 
12-15]. Emerging evidence also suggests that Twist1 
plays a role in cancer stem cells’ expansion, chemo-
therapeutic resistance, and induction of cancer cell 
differentiation into endothelial cells [16-18]. Taken 
together, these crucial roles for Twist1 in cancer and 
the aforementioned non-essential role of Twist1 in 
adult animal suggest that Twist1 is an attractive mo-
lecular target for inhibiting cell invasion, metastasis 
and acquired drug resistance in breast cancers. 
In this study, we developed a luciferase-based 
high throughput screening system to identify small 
molecular inhibitors that can induce Twist1 degrada-
tion in cancer cells from Sigma’s Library of Pharma-
cologically Active Compounds (LOPAC). We report 
that tamoxifen strongly accelerates Twist1 degrada-
tion through the proteasome pathway in an estrogen 
signaling independent manner, resulting in a signifi-
cant inhibition of breast cancer cell invasion and me-
tastasis. 
Materials and Methods 
Cell culture 
The HEK293 cell line with doxycycline-inducible 
Flag-tagged Twist1 expression was described previ-
ously [8, 10]. This HEK293 cell line, the 168FARN and 
4T1 mouse mammary tumor cell lines and the HeLa 
and MDA-MB-435 human cancer cell lines were cul-
tured in Dulbecco’s Modified Eagle’s Medium 
(DMEM), supplemented with 10% fetal calf serum 
(FCS) at 37oC in a tissue culture incubator with 21% of 
O2 and 5% of CO2. 
Plasmid construction 
We used pQCXIH plasmid (Clontech, Mountain 
View, CA) to construct the expression vectors for the 
Twist1-luciferase (Twist1-Luc) fusion protein and the 
luciferase (Luc) control. To construct the 
pQCXIH-Twist1-Luc vector, the coding region of the 
human Twist1 cDNA was amplified by PCR using the 
5’-ttgcggccgccaccatgatgcaggacgtgtc primer with a 
NotI site and the Kozak sequence and the 
5’-ttaccggtgtgggacgcggacatggaccagg primer with an 
AgeI site. The luciferase-coding region was amplified 
by PCR using the 5’-taccggtatggaagacgccaaaaac pri-
mer with an AgeI site and the 
5’-ccttaattaattacacggcgatctttc primer with a PacI site. 
These two amplified DNA fragments were cloned into 
the pQCXIH plasmid by using the NotI, AgeI and 
PacI sites. To construct the pQCXIH-Luc vector, the 





luciferase coding region was amplified by PCR from 
the pGL3-basic vector using the 
5’-gaccggtgccaccatggaagacgccaaaaacat primer with an 
AgeI site and a Kozak sequence and the 
5’-ccttaattaattacacggcgatctttc primer with a PacI site. 
The amplified DNA was cloned into the pQCXIH 
plasmid by using the AgeI and PacI sites. Both ex-
pression vectors were validated by DNA sequencing.  
Screening the Library of Pharmacologically 
Active Compounds (LOPAC), cell transfection 
and luciferase assays 
HeLa cells were seeded in 96-well plate at a 
density of 9000 cells/well and cultured in DMEM 
with 10% of FCS overnight. Cells were transfected 
with pQCXIH-Twist1-Luc or pQCXIH-Luc plasmid 
(250 ng/well) using Lipofectamine 2000 (Invitrogen, 
Carlsbad, CA; 0.75 μl/well), and cultured overnight. 
Then, these transfected cells in 96-well plates with 100 
μl medium were treated with 1 μl of DMSO (vehicle) 
or 1 μl of one of the 1280 compound stock solutions (1 
mM in DMSO) made from the LOPAC library (Sig-
ma-Aldrich, St. Louis, MO). After treating cells for 24 
hours at 37oC in a tissue culture incubator, cells were 
washed with PBS and lysed for luciferase assay as 
described previously [19]. To confirm the screening 
result from tamoxifen treatment, HeLa cells in 24-well 
plate were transfected with pQCXIH-Twist1-Luc or 
pQCXIH-Luc plasmid and a β-galactosidase expres-
sion plasmid. After cells were treated with vehicle 
(ethanol) or tamoxifen (10 μM) for 24 hours, their lu-
ciferase and β-galacrtosidase activities were meas-
ured. The relative luciferase activity was normalized 
to the β-galactosidase activity in each sample. Trans-
fection experiments were performed in duplicates 
with at least one additional repeat.  
Western blot 
Cells treated with tamoxifen, 17β-estradiol, ICI 
182,780, 4-hydroxytamoxifen, cycloheximide and/or 
MG132 (Sigma-Aldrich, St. Louis, MO) in different 
experiments were harvested and lysed on ice for 20 
minutes in a lysis buffer containing 50 mM Tris-HCl 
(pH 7.5), 150 mM NaCl, 0.5 mM EDTA, 0.1% SDS, 1% 
Triton-X 100, 1 mM DTT, 100 μM Na3VO3, 100 μM 
sodium pyrophosphate, and 100 μM sodium fluoride. 
Protein concentrations were measured by using the 
Bradford Protein Assay reagent (Bio-Rad, Hercules, 
CA). Processed cell lysates with 30 μg of protein in 
each were separated by electrophorysis in a 10% 
SDS-PAGE gel. The protein in the gel was blotted onto 
a nitrocellulose membrane. The membrane was 
blocked with 5% fat-free milk or 5% BSA in PBST (PBS 
with 0.1% Tween-20) at room temperature for 1 hour, 
and then incubated with a primary antibody at 4oC 
overnight. This study used the primary antibodies 
against Twist1 (Abcam, Cambridge MA; 1:200 dilu-
tion), phospho-Twist1 (1:1000 dilution)[10], MAPKs 
and phospho-MAPKs (Cell Signaling, Danvers, MA; 
1:1000 dilution) as well as β-actin (Santa Cruz Bio-
technology, Santa Cruz, CA; 1:5000 dilution). After 
washing 3 times with PBST, the membrane was in-
cubated with an appropriate secondary antibody 
conjugated to horseradish peroxidase at room tem-
perature for 1 hour. The membrane was washed 3 
times in PBST and then incubated with a substrate 
solution in an ECL kit to develop a chemilumines-
cence signal. The X-Ray film was exposed at least for 
30 seconds before development. 
RNA isolation and quantitative RT-PCR 
(Q-PCR) 
Total RNA was extracted from tamoxifen-treated 
HEK293 cells with inducible Twist1 expression and 
tamoxifen-treated 4T1 and 168FARN cells with en-
dogenous Twist1 expression using Trizol reagent (Life 
Technologies, Grand Island, NY) according to the 
manufacturer’s protocol. The isolated total RNA was 
further purified using RNeasy columns (Qiagen, Va-
lencia, CA). For TaqMan Q-PCR analysis, total RNA 
was reversely transcribed. Sequence-specific primers 
and fluorescence labeled probes for human Twist1 
and β-actin cDNAs were designed and matched by 
using the Universal Probe Library Center Software 
(Roche, Indianapolis, IN). Relative concentrations of 
Twist1 mRNA were obtained by normalization to 
β-actin mRNA. 
Cell invasion assays 
Cell invasion assay was carried out using the BD 
BioCoat Matrigel Invasion Chamber (BD Biosciences, 
Bedford, MA). 4T1 cells cultured in DMEM with 10% 
FCS were treated with vehicle (ethanol) or 10 uM ta-
moxifen for 24 hours, and then seeded into the upper 
chambers (25000 cells/chamber) with serum-free 
DMEM. The lower chamber was filled with DMEM 
containing 1% FCS as chemoattractant. After cultur-
ing for 24 hours, the cells and Matrigel above the 
membrane were removed with a cotton swab, and the 
cells adherent to the lower surface of the membrane 
were stained with DAPI. The stained cells on the 
air-dried membrane were examined and counted at 
20X magnification under a fluorescence microscope. 
Analysis of 4T1 cell-derived xenograft mam-
mary tumor growth and lung metastasis in 
mice 
4T1 cells were cultured in DMEM with 10% FCS 
to confluence and harvested by trypsin digestion. 
Cells were washed in PBS and resuspended in se-





rum-free DMEM at 1 × 106 cells/ml. Female SCID-bg 
mice aged 6-8 weeks were anesthetized with Avertin 
(50 mg/kg, i.p.). 4T1 Cells (1×105 in 0.1 ml volume) 
were injected into the right second mammary fat pad 
of each mouse. Four days after the injection, mice 
were randomly divided into two groups. One group 
was treated with 50 μl of corn oil (once every 2 days, 
i.p.) for 5 weeks, while another group was treated 
with tamoxifen (5 mg/kg body weight in 50 μl of corn 
oil, once every 2 days, i.p.) for 5 weeks. Tumor length 
and width were measured once a week and tumor 
volume was estimated by (length × width2)/2 as de-
scribed previously [20]. At the experimental end 
point, mice were euthanized, and their lungs were 
dissected out and examined under a stereoscope for 
imaging and counting of metastatic foci seen on the 
lung surface. Then, the lungs were fixed in 4% para-
formaldehype in PBS and embedded in paraffin 
blocks. Coronal lung sections of 5 μm thickness were 
prepared. Five sections with at least a 200 μm interval 
with respect to each other were stained with hema-
toxylin and eosin (H&E) and imaged under a micro-
scope. The total lung area and metastasis tumor area 
on the lung section were measured and the ratio of 
tumor area to lung area were calculated and used as a 
lung metastasis index as described previously [21]. 
Results  
Tamoxifen treatment drastically decreased 
Twist1 protein in cells 
To establish a high throughput screening system 
for identifying bioactive small molecules that reduce 
Twist1 protein in cancer cells, we constructed a 
pQCXIH-Twist1-Luc vector to express the 
Twist1-luciferase fusion protein and a pQCXIH-Luc 
vector to express only the luciferase protein as a con-
trol (Fig. 1A). The relative cellular amounts of both 
Twist1-Luc and luciferase proteins can be conven-
iently measured by their luciferase activities. We 
equally transfected HeLa cells in 96-well plates with 
either pQCXIH-Twist1-Luc or pQCXIH-Luc plasmid, 
followed by treatment with one of the 1280 pharma-
cologically active compounds in the LOPAC library. 
Measurements of luciferase activities in all transfected 
and treated cells led to the identification of several 
small compounds that selectively reduced the lucif-
erase activity in cells transfected with 
pQCXIH-Twist1-Luc plasmid, but had no significant 
effects on the luciferase activity in cells transfected 
with the pQCXIH-Luc plasmid. These compounds 
include tamoxifen citrate (tamoxifen), sertraline, in-
datraline, CGS-12066A, methiothepin, GR 127935, 
parthenolide and MK-886. tamoxifen is a well-known 
SERM for treating ER-positive breast cancer. Ser-
traline, indatraline and CGS-12066A are a selective 
serotonin reuptake inhibitor (SSRI), a serotonin re-
ceptor agonist and a serotonin antagonist, respec-
tively. Methiothepin and GR-127935 are 5-HT1B/1D 
receptor antagonists. Parthenolide is an inhibitor of 
serotonin release from platelets. MK-886 is a potent 
and specific inhibitor of leukotriene biosynthesis. In 
this study, tamoxifen was selected for further charac-
terization because of its known therapeutic role in 
ER-positive breast cancers and the crucial role of 
Twist1 in driving epithelial-mesenchymal transition 
and metastasis in breast cancer cells [2]. 
To validate these screening results, we transi-
ently expressed Twist1-Luc fusion protein or Luc 
protein in HeLa cells in 24-well plates and treated 
these cells with tamoxifen or vehicle (ethanol) for 24 
hours, and measured their luciferase activities. The 
results demonstrated that tamoxifen treatment indeed 
drastically decreased the luciferase activity in cells 
expressing Twist1-Luc protein when compared with 
that in cells expressing the Luc protein only (Fig. 1B). 
These results indicate that tamoxifen treatment can 
selectively reduce Twist1-Luc protein versus the lu-
ciferase protein in transfected HeLa cells. Further-
more, we tested how tamoxifen affected the level of 
Twist1 protein expressed in a stable HEK293 cell line 
with inducible Twist1 expression [8]. Constant Twist1 
expression in these cells was induced by doxycycline 
treatment and the cells were then treated with tamox-
ifen for different time periods. Western blot analysis 
shows that Twist1 protein remained relatively con-
stant in doxycycline-treated cells without tamoxifen 
treatment. However, Twist1 protein was significantly 
reduced in doxycycline-treated cells that were also 
treated with tamoxifen for 6, 10 and 24 hours (Fig. 1C). 
Consistently, Twist1 protein in these cells was de-
creased in a tamoxifen dose-dependent manner (Fig. 
1D). Moreover, we treated 168FARN mouse mam-
mary tumor cells, MDA-MB-435 human cancer cells, 
and 4T1 mouse mammary tumor cells that express 
endogenous Twist1 with tamoxifen and found that 
tamoxifen treatment also significantly decreased 
Twist1 protein in these cells in both a tamoxi-
fen-dependent and a time-dependent manner (Fig. 1E 
and F). These results clearly indicated that tamoxifen 
treatment can effectively decrease Twist1 protein in 
cells.  






Figure 1. Tamoxifen treatment decreases the cellular levels of Twist1 protein. A. In pQCXIH-Luc and pQCXIH-Twist1-Luc plasmids, the expression of luciferase or 
Twist1-Luciferase was driven by the CMV promoter. B. HeLa cells transfected with pQCXIH-Luc or pQCXIH-Twist1-Luc plasmids and with a β-galactosidase expression 
plasmid were treated with vehicle (ethanol) or tamoxifen (10 μM) for 24 hours. Then, the luciferase activity was measured and normalized to the β-galactosidase activity for each 
sample. Relative luciferase activity was calculated by (Luc activity in tamoxifen-treated cells/Luc activity in vehicle-treated cells) × 100. Data are presented as mean ± SD. ***, P 
< 0.0001 by t test. C. HEK293 cells with an inducible Twist1 expression system were treated with 1 μg/ml of doxycycline for 12 hours to induce stable Twist1 expression and 
then co-treated with 1 μg/ml of doxycycline and vehicle or 10 μM of tamoxifen for the time periods as indicated. HEK293 cells without inducible Twist1 expression served as a 
negative control (Lane 1). Western blot analyses were performed with Twist1 and β-actin antibodies. D. HEK293 cells with inducible Twist1 expression were treated with 1 
μg/ml of doxycycline for 12 hours, and then co-treated with 1 μg/ml of doxycycline and different concentrations of tamoxifen as indicated for 24 hours before Western blotting 
was performed. E. Western blot analyses of Twist1 in 168FARN and 4T1 cells treated with vehicle or tamoxifen (10 μM) for different time periods as indicated. F. Western blot 
analyses of Twist1 in 168FARN and MDA-MB-435 cells treated with the indicated concentrations of tamoxifen for 24 hours. Results shown in panels B to F are representative 
results of at least three repeat assays. 
 
Tamoxifen significantly accelerated Twist1 
protein degradation in cells 
To determine whether tamoxifen could change 
Twist1 mRNA levels, we treated HEK293 cells with 
inducible Twist1 expression and 168FARN and 4T1 
mammary tumor cells with endogenous Twist1 ex-
pression with different concentrations of tamoxifen 
for 24 hours and measured Twist1 mRNA by qPCR. 
Our results demonstrate that tamoxifen treatment had 
no effect on Twist1 mRNA levels in HEK293 and 4T1 
cells and even slightly increased Twist1 mRNA levels 
in 168FARN cells (Fig. 2A). These results indicate that 
tamoxifen-induced decreases in Twist1 protein in 
these cells are not due to changes at its mRNA level.  
To determine whether tamoxifen could alter 
Twist1 protein stability, we treated HEK293 cells with 
inducible Twist1 expression and 168FARN cells with 
endogenous Twist1 expression with either cyclo-
heximide or cycloheximide and tamoxifen, and then 
examined Twist1 protein degradation at different 
time points. The results from Western blotting show 
that Twist1 protein was degraded much faster in ta-
moxifen-treated cells versus cells without tamoxifen 
treatment upon inhibition of protein synthesis by cy-
cloheximide; the difference in Twist1 protein levels 
was particularly evident after tamoxifen treatment for 
6 hours (Fig. 2B and C). These results demonstrated 
that tamoxifen treatment significantly accelerates 
Twist1 protein degradation.  
Tamoxifen induces Twist1 degradation 
through the proteasome-dependent pathway 
in an estrogen signaling independent manner 
To elucidate the mechanism of tamoxi-
fen-induced Twist1 degradation, we examined 
whether inhibition of proteasome-mediated protein 
degradation pathway could diminish the effect of 





tamoxifen on Twist1 protein stability. We treated 
HEK293 cells with inducible Twist1 expression and 
168FARN cells with endogenous Twist1 expression 
with the proteasome inhibitor MG132 or with MG132 
and tamoxifen, followed by analysis of Twist1 protein 
levels at different time points. We found that Twist1 
protein was accumulated in a time-dependent manner 
in cells treated with MG132 alone, suggesting that 
Twist1 was normally degraded through the pro-
teasome-mediated pathway. Interestingly, Twist1 
protein was maintained at the same level through all 
the time points in cells treated with both MG132 and 
tamoxifen, suggesting that tamoxifen-accelerated 
Twist1 degradation is mostly mediated by the pro-
teasome pathway (Fig. 3A and B). These results also 
suggest that tamoxifen can prevent Twist1 accumula-
tion in proteasome-inhibited cells through other un-
known pathways.  
Next, we examined whether tamoxifen-induced 
Twist1 degradation is related to estrogen signaling. 
First, we measured ERα and ERβ mRNA levels by 
Q-PCR and their protein levels by Western blot in 
HEK293 cells with inducible Twist1 expression and 
4T1 and 168FARN cells with endogenous Twist1 ex-
pression. However, we did not detect any obvious 
ERα or ERβ expression in these cells (data not shown). 
We also treated these three cell lines with 
17β-estradiol, ICI 182780 (a pure ER antagonist), 
4-hydroxytamoxifen and tamoxifen. We found that 
17β-estradiol or ICI 182780 treatment did not change 
Twist1 protein levels, indicating that either activation 
or inhibition of estrogen signaling pathways was not 
related to the tamoxifen-induced Twist1 degradation 
observed in these cells (Fig. 3C). We also found that 
4-hydroxytamoxifen played a similar role as tamoxi-
fen to downregulate Twist1 protein in these cells, 
which was not surprising since they are similar com-
pounds (Fig. 3C).  
We have previously reported that phosphoryla-
tion of serine 68 by MAPKs stabilizes Twist1 protein 
[10]. Therefore, we examined MAPK activities, 
phosphorylated serine 68-Twist1 and total Twist1 in 
tamoxifen-treated 168FARN cells. Our results 
demonstrated that there were no significant changes 
in either total or activated ERK1/2, p38 and JNK MAP 
kinases in 168FARN cells treated with or without ta-
moxifen (Fig. 3D). Consistently, tamoxifen treatment 
also did not change the level of phosphorylated serine 
68-Twist1, although it significantly reduced the total 
Twist1 level in 168FARN cells (Fig. 3E). These results 
suggest that tamoxi-
fen-promoted Twist1 degra-
dation is independent of 
phosphorylation of the serine 
68 residue in Twist1.  
 
Figure 2. Tamoxifen accelerates Twist1 
protein degradation. A. Q-PCR analyses of 
Twist1 mRNA in HEK293 cells with inducible 
Twist1 expression and 4T1 and 168FARN cells 
with endogenous Twist1 expression. These 
cells were treated with different concentra-
tions of tamoxifen for 24 hours. B. Western 
blot analysis of Twist1 in HEK293 cells with 
inducible Twist1 expression. Cells were 
treated with 1 μg/ml of doxycycline for 12 
hours to induce Twist1 expression, then 
treated with 50 μM of cycloheximide to inhibit 
protein synthesis and with vehicle (ethanol) or 
10 μM of tamoxifen for different time periods 
as indicated. Analysis of β-actin served as a 
loading control. HEK293 parent cells without 
Twist1 expression (Lane 1) served as a nega-
tive control. Band intensities were measured 
by densitometry and presented in the right 
panel. The half-life time of Twist1 protein is 
4.41 hours in the vehicle-treated cells or 3.80 
hours in the tamoxifen-treated cells. C. 
Western blot analysis of Twist1 in 168FARN 
cells treated with vehicle (ethanol) or 10 μM of 
tamoxifen and with 50 μM of cycloheximide 
for different time periods as indicated. Band 
intensities were measured by densitometry 
and presented in the right panel. The half-life 
time of Twist1 protein is 4.91 hours in the 
vehicle-treated cells or 4.26 hours in the 
tamoxifen-treated cells. Results shown in 
panels B and C are representative results of at 
least three repeat assays. 






Figure 3. Tamoxifen-accelerated Twist1 degradation is dependent on the proteasome pathway, but is independent of estrogen and MAPK signaling 
pathways. A. Western blot analysis of Twist1 in HEK293 cells with inducible Twist1 expression (HEK293+Twist1) after cells were treated with 20 μM of MG132 and vehicle 
(ethanol) or 10 μM of tamoxifen for different time periods as indicated. HEK293 parent cells without Twist1 expression served as a negative control. B. Western blot analysis 
of Twist1 in 168FARN cells treated with 20 μM of MG132 and vehicle (ethanol) or 10 μM of tamoxifen. C. Western blot analysis of Twist1 in HEK293+Twist1, 4T1 and 168FARN 
cells treated for 24 hours with vehicle (V, ethanol), or 10 μM of 17β-estradiol (E2), ICI 182,780 (ICI), 4-hydroxytamoxifen (4OH) and tamoxifen (Tam) as indicated. D. Western 
blot analysis of active phospho-Erk1/2, total Erk1/2, active phospho-p38, total p38, active phospho-JNK, and total JNK in 168FARN cells treated with different concentrations of 
tamoxifen for 6 hours. E. Western blot analysis of phospho-Ser68-Twist1 and total Twist1 in 168FARN cells treated with different concentrations of tamoxifen for 6 hours. 
Results shown in all panels are representative results of at least three repeat assays. 
 
Tamoxifen treatment reduces the invasive 
capability of mammary tumor cells 
Twist1 is known to increase breast cancer cell 
invasiveness [2, 7, 8]. Therefore, we treated 4T1 
mammary tumor cells with endogenous Twist1 ex-
pression with tamoxifen and measured the impact of 
tamoxifen treatment on cell invasion. We found that 
tamoxifen treatment significantly reduced the number 
of 4T1 cells that could invade through a layer of Mat-
rigel in a transwell cell invasion assay system (Fig. 4A 
and B). These results suggest that tamoxifen-induced 
Twist1 degradation can partially inhibit EMT and 
invasiveness of breast cancer cells. 
Tamoxifen treatment significantly reduced the 
lung metastasis derived from an ER-negative 
mammary tumor cells in mice 
It has been previously reported that knockdown 
of Twist1 by expressing shRNAs in 4T1 mammary 
tumor cells significantly inhibits its metastasis to lung 
in mice [7, 8]. To test whether a tamoxifen-induced 
decrease in Twist1 protein could reduce lung metas-
tasis in ER-negative 4T1 mammary tumor cells, we 
injected 4T1 cells into the mammary fat pads of SCID 
mice, followed by tamoxifen or vehicle (core oil) 
treatment and examination of primary tumor weights 
and lung metastases. We found that tamoxifen treat-
ment had no significant influence on primary tumor 
weight (Fig. 5A), which is consistent with previous 
studies showing knockdown Twist1 had no obvious 
effect on primary tumor growth in mice [8]. However, 
tamoxifen treatment significantly reduced the number 
of metastatic foci observed on the lung surface (Fig. 5B 
and C) and the lung metastasis index calculated based 
on the metastasis area versus the lung area (Fig. 5D 
and E). These results indicate that tamoxifen treat-
ment can significantly inhibit the lung metastasis de-
rived from the xenograft tumors of the ER-negative 
4T1 mammary tumor cells in the mammary gland. 






Figure 4. Tamoxifen treatment decreases cell invasiveness of 4T1 
mammary tumor cells. 4T1 cells pre-treated with vehicle (ethanol) or 10 μM 
tamoxifen for 24 hours were seeded in the upper chambers of the transwell invasion 
assay system (2.5 × 104 cells/chamber). The upper chamber contains serum-free 
medium with vehicle (ethanol) or 10 μM tamoxifen, while the lower chamber 
contains medium with 1% serum and vehicle (ethanol) or 10 μM tamoxifen. After 
culturing for 24 hours, invaded cells on the lower side of the membrane were stained 
with DAPI, and imaged (Panel A) and counted (Panel B) under a fluorescence mi-
croscope. **, P < 0.01 by two-tailed Student’s t test, n = 5 for each.  
 
Discussion 
The crucial role of Twist1 in cancer metastasis 
and drug resistance and the nonessential role of 
Twist1 in adult general health make Twist1 a prom-
ising target for inhibiting cancer with tolerable ad-
verse effects in adult patients. With the primary goal 
to identify small molecule inhibitors that can induce 
Twist1 degradation, we screened the LOPAC library 
with 1280 pharmacologically active compounds. This 
library was chosen because the in vivo metabolic ki-
netics and toxicity of these compounds have been well 
characterized. Once an inhibitor is identified, it can be 
rapidly used in translational studies and possibly 
even in clinical trials. Among the several compounds 
identified from our screening, we selected tamoxifen 
as a leading compound to characterize its role in 
Twist1 degradation because tamoxifen has been ex-
tensively used in the treatment of ER-positive breast 
cancers.  
Our results demonstrated that tamoxifen treat-
ment significantly accelerated Twist1 protein degra-
dation in multiple cell types, including HEK293 kid-
ney epithelial cells with ectopically expressed Twist1 
and 4T1 and 168FARN mammary tumor cells with 
endogenously expressed Twist1. Furthermore, the 
tamoxifen-induced Twist1 degradation could be 
blocked by the proteasome inhibitor MG132, indicat-
ing that tamoxifen stimulates Twist1 degradation via 
the proteasome pathway. Importantly, tamoxifen 
treatment also significantly reduced the invasive be-
havior and metastasis capability of the 4T1 mammary 
tumor cells in cell culture and mice. 4T1 cells are 
ER-negative mammary tumor cells and tamoxifen 
showed no obvious effects on 4T1 cell proliferation in 
culture and xenograft tumor growth in the mouse 
mammary glands. It was also demonstrated that 
knockdown of Twist1 in 4T1 cells significantly inhib-
ited the invasion and metastasis of 4T1 cells in culture 
and 4T1 xenograft tumors in mice without signifi-
cantly affecting the proliferation and xenograft tumor 
growth of 4T1 cells [7, 8]. Therefore, the phenotypes of 
tamoxifen-treated 4T1 cells and tumors closely copy 
the phenotypes of 4T1 tumor cells with Twist1 
knockdown, suggesting that tamoxifen-decreased 
Twist1 is responsible, at least in part, for the reduced 
invasive behavior and metastasis of 4T1 cells and 
tumors. 
After being administered to patients, tamoxifen 
is metabolized into 4-OH-tamoxifen, which binds to 
ER and results in inhibition of its transcriptional ac-
tivity in certain tissues such as the breast tissue but 
activation of its activity in certain other tissues such as 
the uterus. Due to its inhibitory role in the growth of 
ER-positive breast cancers that rely on estrogen sig-
naling to survive and grow, tamoxifen has been ex-
tensively used to treat ER-positive breast cancers [22]. 
Tamoxifen treatment can inhibit breast cancer relapse 
after surgery, reduce the risk of invasive breast cancer 
progression from ductal carcinoma in situ (DCIS) and 
stop or even shrink some of the metastatic breast tu-
mors. It is conceivable that some of these pharmaceu-
tical effects of tamoxifen may be independent of es-
trogen signaling. In this study, we demonstrated that 
tamoxifen-induced Twist1 degradation is independ-
ent of estrogen signaling, supporting the notion that 
additional tamoxifen targets exist in breast cancer 
cells including ER-negative breast cancer cells. Pre-
vious studies also showed that tamoxifen displays 
chemopreventative activity against ER-negative 
breast cancer and other cancers [23-25]. Specifically, 
pharmacological concentrations of tamoxifen induce 
apoptosis of ER-negative breast cancer cells by mod-
ulating the activities of PI3K/AKT and ERK protein 
kinases [26], and tamoxifen also suppresses both tu-
mor growth and metastasis derived from an 
ER-negative basal-like breast cancer cell line in Balb/c 
mice [27]. On the other hand, tamoxifen exhibits cer-
tain detrimental effects on cancer therapy. For exam-
ple, tamoxifen inhibits the immune response by re-





ducing the expression of IL-18, the numbers of CD4+ T 
cells, the activity of natural killer cells, the function of 
monocytes, the development of antibodies and the 
differentiation and activation of dendritic cells and by 
increasing the expression of TGF-β1 [28-34]. Taken 
together, these studies suggest that tamoxifen acts not 
only by binding to ER to inhibit ER-positive breast 
cancers but also by affecting other yet unknown mo-
lecular targets, so called “off targets”, to either facili-
tate or deduct from overall therapeutic outcomes of 
tamoxifen. Therefore, identification and characteriza-
tion of all direct molecular targets of tamoxifen and 
their regulated pathways may help to maximize its 
therapeutic efficacy for ER-positive breast cancers and 
extend its applications to ER-negative and other un-
related cancers. 
Our results show that tamoxifen-induced Twist1 
degradation happened after cells were treated for a 
relatively long period of time, suggesting an indirect 
molecular mechanism responsible for tamoxi-
fen-accelerated degradation of Twist1. We have pre-
viously shown that MAPK-mediated phosphorylation 
of Twist1 at serine 68 stabilizes Twist1 protein to en-
hance its cellular function [10]. Thus, we examined 
whether tamoxifen could inhibit the activities of 
ERK1/2, p38 and JNK kinases and decrease the 
phosphorylation level of Twist1 in ER-negative 
mammary tumor cells with Twist1 expression. How-
ever, we found no significant changes. We also ex-
amined any possible influences of estrogen signaling 
on Twist1 protein degradation in these cells and 
found no obvious effect of estrogen signaling on 
Twist1 degradation. Therefore, despite the above ef-
forts that were made, the direct target(s) of tamoxifen 
linked to Twist1 degradation in ER-negative breast 





Figure 5. Tamoxifen treatment inhibits lung metastasis derived from the 4T1 cell xenograft tumors in mice. A. There was no significant difference in the growth 
of 4T1 cell xenograft tumors in the mammary fat pads of vehicle (corn oil) or tamoxifen-treated SCID mice (n = 5 for each). B. Representative images taken from the lungs of 
vehicle or tamoxifen-treated SCID mice carrying 4T1 xenograft mammary tumors. *, indicate the metastasis foci on the lung surface. C. The average numbers of the metastasis 
foci observed in the vehicle-treated or tamoxifen-treated SCID mice (n = 5 each) carrying 4T1 xenograft mammary tumors. *, P < 0.05 by two-tailed Student’s t test. D. 
H&E-stained lung sections prepared from vehicle- or tamoxifen-treated SCID mice carrying 4T1 xenograft mammary tumors. M, metastasis developed in the lung tissue. E. The 
average value of the relative lung metastasis areas is larger in the vehicle-treated versus tamoxifen-treated SCID mice (n = 5 each) with 4T1 xenograft mammary tumors. **, P 
< 0.01 by two tailed Student’s t test. 
 





It should be of interesting to compare the ta-
moxifen doses used to induce Twist1 degradation and 
inhibit cell invasion and metastasis in ER-negative 
breast cancer cells and that used to inhibit ER-positive 
breast cancer cells in vitro and in vivo. We used 10 μM 
tamoxifen to induce Twist1 degradation in 
ER-negative breast cancer cells in this study, which 
was about 10 times higher than the 4-OH-tamoxifen 
concentration used to inhibit the growth of 
ER-positive breast cancer cells such as MCF-7 cells in 
culture. In mice bearing xenograft tumors derived 
from ER-negative breast cancer cells, administration 
of 5 mg/kg tamoxifen every other day (2.5 
mg/kg/day) significantly reduced their metastasis. 
This dosage is similar to that used to inhibit the 
growth of xenograft tumors derived from the MCF-7 
ER-positive breast cancer cells. For example, it has 
been shown that tamoxifen doses at 5, 25, 50 or 100 
μg/mouse/day, which are equal to 0.25, 1.25, 2.5 or 5 
mg/kg/day for a 20 g mouse, could effectively inhibit 
the growth of MCF-7 cell-derived xenograft tumors in 
mice [35]. Furthermore, it has previously estimated 
that the drug dose used in mice is about 12.3 fold 
higher than the drug dose used in human patients 
according to their body surface areas [36]. Accord-
ingly, a tamoxifen dose of 2.5 mg/kg/day for a 20 g 
mouse can be translated to a dose of 0.20 mg/kg/day 
for a 60 kg human being. Currently, ER-positive 
breast cancer patients are treated with 20 mg of ta-
moxifen (P.O. per day), which is equal to a dose of 
0.333 mg/kg/day for a 60 kg patient. Therefore, the 
relative tomoxifen dose used to treat our mice with 
ER-negative xenograft tumors is very close to what 
used to treat ER-positive breast cancer patients. 
In summary, we have identified tamoxifen as a 
small molecular inhibitor that accelerates Twist1 
degradation and suppresses Twist1-mediated inva-
sion and metastasis of ER-negative breast cancer cells. 
These findings not only provide a molecular explana-
tion for the tamoxifen-mediated inhibition of certain 
ER-negative cancer metastasis but also suggest im-
portant implications for the use of tamoxifen in the 
treatment of ER-negative breast cancers with high 
levels of Twist1 expression. 
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